Prostanoid-mediated inotropic responses are attenuated in failing human and rat ventricular myocardium

European Journal of Pharmacology

Volumn 686, Issue 1-3, 2012, Pages 66-73

  Riise, Jon ^a   Nguyen, Cam H T ^a   Hussain, Rizwan I ^a   Dahl, Christen P ^a,b   Ege, Maren S ^a   Osnes, Jan Bjorn ^a   Skomedal, Tor ^a   Sandnes, Dagny L ^a   Levy, Finn Olav ^a   Krobert, Kurt A ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Contractility; Desensitization; Heart failure; Myocardial function; Myosin light chain; Prostaglandin

Indexed keywords

ATROPINE; FLUPROSTENOL; ILOPROST; MESSENGER RNA; MYOSIN LIGHT CHAIN 2; PRAZOSIN; PROSTANOID; PROSTANOID FP RECEPTOR; PROSTANOID RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME REGULATION; FEMALE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONTRACTILE FORCE; HUMAN; HUMAN TISSUE; INOTROPISM; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; TREATMENT RESPONSE; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALPROSTADIL; ANIMALS; CARDIAC MYOSINS; CHILD; DISEASE MODELS, ANIMAL; FEMALE; HEART FAILURE; HEART VENTRICLES; HUMANS; ILOPROST; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; MYOSIN LIGHT CHAINS; PROSTAGLANDINS F, SYNTHETIC; RATS; RECEPTORS, PROSTAGLANDIN; VENTRICULAR FUNCTION;

EID: 84861588106     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.04.022     Document Type: Article

References (35)

1. ALLHAT Collaborative Research Group Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group JAMA 283 2000 1967 1975
2. G.S. Bleumink, J. Feenstra, M.C. Sturkenboom, and B.H. Stricker Nonsteroidal anti-inflammatory drugs and heart failure Drugs 63 2003 525 534
3. 4 Naunyn Schmiedebergs Arch. Pharmacol. 369 2004 616 628
4. R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, K. Horgan, C. Lines, R. Riddell, D. Morton, A. Lanas, M.A. Konstam, and J.A. Baron Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N. Engl. J. Med. 352 2005 1092 1102
5. R.M. Breyer, C.K. Bagdassarian, S.A. Myers, and M.D. Breyer Prostanoid receptors: subtypes and signaling Annu. Rev. Pharmacol. Toxicol. 41 2001 661 690
6. R.M. Califf, K.F. Adams, W.J. McKenna, M. Gheorghiade, B.F. Uretsky, S.E. McNulty, H. Darius, K. Schulman, F. Zannad, E. Handberg-Thurmond, F.E. Harrell Jr., W. Wheeler, J. Soler-Soler, and K. Swedberg A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST) Am. Heart J. 134 1997 44 54
7. R.M. Delgado, M.A. Nawar, A.M. Zewail, B. Kar, W.K. Vaughn, K.K. Wu, N. Aleksic, N. Sivasubramanian, K. McKay, D.L. Mann, and J.T. Willerson Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure Circulation 109 2004 1428 1433
8. R. Doi, T. Masuyama, K. Yamamoto, Y. Doi, T. Mano, Y. Sakata, K. Ono, T. Kuzuya, S. Hirota, T. Koyama, T. Miwa, and M. Hori Development of different phenotypes of hypertensive heart failure: systolic versus diastolic failure in Dahl salt-sensitive rats J. Hypertens. 18 2000 111 120
9. D.R. Hathaway, and J.R. Haeberle A radioimmunoblotting method for measuring myosin light chain phosphorylation levels in smooth muscle Am. J. Physiol. 249 1985 C345 C351
10. G.A. Haywood, K.F. Adams Jr., M. Gheorghiade, and W.J. McKenna Is there a role for epoprostenol in the management of heart failure? Am. J. Cardiol. 75 1995 44A 50A
11. R.I. Hussain, E. Qvigstad, J.A. Birkeland, H. Eikemo, A. Glende, I. Sjaastad, T. Skomedal, J.B. Osnes, F.O. Levy, and K.A. Krobert Activation of muscarinic receptors elicits inotropic responses in ventricular muscle from rats with heart failure through myosin light chain phosphorylation Br. J. Pharmacol. 156 2009 575 586
12. M. Inoko, Y. Kihara, I. Morii, H. Fujiwara, and S. Sasayama Transition from compensatory hypertrophy to dilated, failing left ventricles in Dahl salt-sensitive rats Am. J. Physiol. 267 1994 H2471 H2482
13. q in cDNA-transfected Chinese hamster ovary cells Biochem. Biophys. Res. Commun. 200 1994 756 762
14. Y. Kihara, and S. Sasayama Transition from compensatory hypertrophy to dilated failing left ventricle in Dahl-Iwai salt-sensitive rats Am. J. Hypertens. 10 1997 78S 82S
15. M. Kiriyama, F. Ushikubi, T. Kobayashi, M. Hirata, Y. Sugimoto, and S. Narumiya Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells Br. J. Pharmacol. 122 1997 217 224
16. K.T. Kruse-Elliott, and N.C. Olson CGS 8515 and indomethacin attenuate cytokine-induced cardiopulmonary dysfunction in pigs Am. J. Physiol. 264 1993 H1076 H1086
17. G.A. MacGowan, and A.P. Koretsky Inotropic and energetic effects of altering the force-calcium relationship: mechanisms, experimental results, and potential molecular targets J. Card. Fail. 6 2000 144 156
18. M. Mamdani, D.N. Juurlink, D.S. Lee, P.A. Rochon, A. Kopp, G. Naglie, P.C. Austin, A. Laupacis, and T.A. Stukel Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study Lancet 363 2004 1751 1756
19. T. Metsa-Ketela Cyclic AMP-dependent and -independent effects of prostaglandins on the contraction-relaxation cycle of spontaneously beating isolated rat atria Acta Physiol. Scand. 112 1981 481 485
20. G. Montalescot, G. Drobinski, P. Meurin, J. Maclouf, I. Sotirov, F. Philippe, R. Choussat, E. Morin, and D. Thomas Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure Am. J. Cardiol. 82 1998 749 755
21. J. Myslivecek, and S. Trojan The importance of the prolonged postnatal period in determination of heart atrial muscarinic receptor and beta-adrenoceptor densities Life Sci. 73 2003 3289 3296
22. J. Neumann, T. Eschenhagen, L.R. Jones, B. Linck, W. Schmitz, H. Scholz, and N. Zimmermann Increased expression of cardiac phosphatases in patients with end-stage heart failure J. Mol. Cell. Cardiol. 29 1997 265 272
23. 2 alpha J. Pharmacol. Exp. Ther. 244 1988 844 851
24. J.H. Patterson, K.F. Adams Jr., M. Gheorghiade, R.C. Bourge, C.A. Sueta, S.W. Clarke, J.P. Jankowski, C.L. Shaffer, and R.A. McKinnis Acute hemodynamic effects of the prostacyclin analog 15AU81 in severe congestive heart failure Am. J. Cardiol. 75 1995 26A 33A
25. K.H. Pitkala, T.E. Strandberg, and R.S. Tilvis Worsening heart failure associated with COX-2 inhibitors Am. J. Med. 112 2002 424 426
26. K. Pönicke, C. Giessler, M. Grapow, I. Heinroth-Hoffmann, K. Becker, B. Osten, and O.E. Brodde FP-receptor mediated trophic effects of prostanoids in rat ventricular cardiomyocytes Br. J. Pharmacol. 129 2000 1723 1731
27. J. Riise, C.H. Nguyen, E. Qvigstad, D.L. Sandnes, J.B. Osnes, T. Skomedal, F.O. Levy, and K.A. Krobert Prostanoid F receptors elicit an inotropic effect in rat left ventricle by enhancing myosin light chain phosphorylation Cardiovasc. Res. 80 2008 407 415
28. W. Serra, L. Musiari, D. Ardissino, T. Gherli, and A. Montanari Benefit of prostaglandin infusion in severe heart failure: preliminary clinical experience of repetitive administration Int. J. Cardiol. 146 2011 e10 e15
29. T. Skomedal, K. Borthne, H. Aass, O. Geiran, and J.B. Osnes Comparison between alpha-1 adrenoceptor-mediated and beta adrenoceptor-mediated inotropic components elicited by norepinephrine in failing human ventricular muscle J. Pharmacol. Exp. Ther. 280 1997 721 729
30. S.D. Solomon, J.J. McMurray, M.A. Pfeffer, J. Wittes, R. Fowler, P. Finn, W.F. Anderson, A. Zauber, E. Hawk, and M. Bertagnolli Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N. Engl. J. Med. 352 2005 1071 1080
31. C.A. Sueta, M. Gheorghiade, K.F. Adams Jr., R.C. Bourge, S. Murali, B.F. Uretsky, M.R. Pritzker, M.D. McGoon, S.M. Butman, S.H. Grossman, J.W. Crow, C.L. Shaffer, and M.D. Thorn Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group Am. J. Cardiol. 75 1995 34A 43A
32. 1 on pulmonary circulation in patients with pulmonary hypertension Br. Heart J. 40 1978 1397 1401
33. 2alpha mediate inflammatory tachycardia Nat. Med. 11 2005 562 566
34. H. Viko, J.B. Osnes, A.E. Sjetnan, and T. Skomedal Improved isolation of cardiomyocytes by trypsination in addition to collagenase treatment Pharmacol. Toxicol. 76 1995 68 71
35. 2-type 1 receptor increases rat atrial contractility via a Y-27632-sensitive pathway Prostaglandins Other Lipid Mediat. 70 2002 91 105